Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL559048 | 1.00 | MEN1 (0.39) | MEN1KMT2ASMN1; SMN2TSHRMAPK1 | |
| SCHEMBL1154318 | 1.00 | MEN1 (0.39) | MEN1KMT2ASMN1; SMN2TSHRMAPK1 | |
| SCHEMBL525920 | 0.96 | — | — | |
| SCHEMBL5558812 | 0.86 | — | — | |
| SCHEMBL16328524 | 0.86 | MEN1 (0.31) | MEN1KMT2A | |
| SCHEMBL24936533 | 0.86 | KDM4E (0.36) | MEN1KMT2ASMN1; SMN2TSHRALDH1A1 | |
| SCHEMBL12143358 | 0.86 | MEN1 (0.35) | MEN1KMT2A | |
| SCHEMBL22515372 | 0.86 | KDM4E (0.36) | MEN1KMT2ASMN1; SMN2TSHRALDH1A1 | |
| SCHEMBL16329702 | 0.86 | ALDH1A1 (0.43) | MEN1KMT2ATSHRALDH1A1RAB9A | |
| SCHEMBL16359227 | 0.86 | MEN1 (0.35) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3673921-A1 | MATERIALS AND METHODS FOR CONJUGATING A WATER SOLUBLE FATTY ACID DERIVATIVE TO A PROTEIN | Baxalta GmbH (CH) | 2020-07-01 | — | — | EP | claimed |
| EP-2654794-B1 | MATERIALS AND METHODS FOR CONJUGATING A WATER SOLUBLE FATTY ACID DERIVATIVE TO A PROTEIN | Baxalta GmbH (CH) | 2020-03-04 | — | — | EP | claimed |
| US-8945897-B2 | Materials and methods for conjugating a water soluble fatty acid derivative to a protein | BAXTER INTERNATIONAL INC. (US) | 2015-02-03 | — | — | US | claimed |
| EP-2654794-A1 | MATERIALS AND METHODS FOR CONJUGATING A WATER SOLUBLE FATTY ACID DERIVATIVE TO A PROTEIN | Baxter International Inc (US) | 2013-10-30 | — | — | EP | claimed |
| US-20120190096-A1 | MATERIALS AND METHODS FOR CONJUGATING A WATER SOLUBLE FATTY ACID DERIVATIVE TO A PROTEIN | BAXTER HEALTHCARE S.A. (CH) | 2012-07-26 | — | — | US | claimed |
| WO-2012087838-A1 | MATERIALS AND METHODS FOR CONJUGATING A WATER SOLUBLE FATTY ACID DERIVATIVE TO A PROTEIN | BAXTER INTERNATIONAL INC. (US) | 2012-06-28 | — | — | WO | claimed |
| EP-3673921-A1 | MATERIALS AND METHODS FOR CONJUGATING A WATER SOLUBLE FATTY ACID DERIVATIVE TO A PROTEIN | Baxalta GmbH (CH) | 2020-07-01 | — | — | EP | disclosed |
| EP-2654794-B1 | MATERIALS AND METHODS FOR CONJUGATING A WATER SOLUBLE FATTY ACID DERIVATIVE TO A PROTEIN | Baxalta GmbH (CH) | 2020-03-04 | — | — | EP | disclosed |
| US-8945897-B2 | Materials and methods for conjugating a water soluble fatty acid derivative to a protein | BAXTER INTERNATIONAL INC. (US) | 2015-02-03 | — | — | US | disclosed |
| EP-2654794-A1 | MATERIALS AND METHODS FOR CONJUGATING A WATER SOLUBLE FATTY ACID DERIVATIVE TO A PROTEIN | Baxter International Inc (US) | 2013-10-30 | — | — | EP | disclosed |
| US-20120190096-A1 | MATERIALS AND METHODS FOR CONJUGATING A WATER SOLUBLE FATTY ACID DERIVATIVE TO A PROTEIN | BAXTER HEALTHCARE S.A. (CH) | 2012-07-26 | — | — | US | disclosed |
| WO-2012087838-A1 | MATERIALS AND METHODS FOR CONJUGATING A WATER SOLUBLE FATTY ACID DERIVATIVE TO A PROTEIN | BAXTER INTERNATIONAL INC. (US) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190096-A1 | MATERIALS AND METHODS FOR CONJUGATING A WATER SOLUBLE FATTY ACID DERIVATIVE TO A PROTEIN | FABP1, FABP4, FABP5 | MEN1 4267/4885KMT2A 4086/4885SMN1; SMN2 2992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.